MedWatch

Tresiba approval would mean massive boost to Novo share

Novo Nordisk’s shareholders will have a field day if the FDA decides to approve diabetes drug Tresiba for marketing in the US, Nordea believes.

Foto: Jens Lindhe

10% - that is how much the price of the Novo Nordisk share is expected to go up if the FDA approves the company’s long-acting insulin Tresiba for the US market, says pan-Nordic bank Nordea.

“What's most important for Novo Nordisk’s growth story are the new products in development. In this regard, the group is facing possible approval of its insulin Tresiba in the US, presumably in early October. We see a great probability (90%) of approval, which could trigger an increase in the share price of up to 10%. If approval is postponed, which we see as a low probability (10%), the share price is expected to drop by 15%,” Jesper Bamberger, Senior Equity Advisor at Nordea, writes in a commentary, adding:

Allerede abonnent? Log ind.

Læs hele artiklen

Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.

  • Adgang til alle låste artikler
  • Modtag vores daglige nyhedsbreve
  • Fuld adgang til vores app
Der skete en fejl. Prøv venligst igen senere

Få fuld adgang til dig og dine kollegaer.

Start et gratis virksomhedsprøveabonnement

Mere fra MedWatch

Relaterede

Seneste nyt

MedWatch job

Se flere jobs

Se flere jobs

Watch job

Se flere jobs

Se flere jobs

Latest news

Seneste nyt fra Watch Medier